市場調査レポート
商品コード
1064487

プロテアソーム・リソソーム・オートファジー経路による標的タンパク質分解 (TPD) (2022年):業界情勢の分析 - ステークホルダー、技術、パイプライン、提携、資金調達

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing

出版日: | 発行: La Merie Publishing | ページ情報: 英文 553 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: EURを日本円(税抜)に換算
本日の銀行送金レート: 1EUR=165.43円
プロテアソーム・リソソーム・オートファジー経路による標的タンパク質分解 (TPD) (2022年):業界情勢の分析 - ステークホルダー、技術、パイプライン、提携、資金調達
出版日: 2022年03月10日
発行: La Merie Publishing
ページ情報: 英文 553 Pages
納期: 即納可能 即納可能とは
担当者のコメント
標的タンパク質分解 (TPD)技術にフォーカスし、プラットフォームを有する技術プロファイル及び技術提供企業、メガファーマのM&A/ライセンス、対象候補医薬品、IPO、ベンチャーキャピタルによる資金調達、Licensing deal、Molecular gluesおよびPROTACsの臨床および前臨床など、2022年3月時点における最新のグローバルトレンドを553ページの内容でまとめた構成です。2020年度の旧版は大手製薬会社様を中心に幅広く引き合いをいただき、今回の更新版も今年度末注目のレポートになります
  • 全表示
  • 概要
  • 目次
概要

標的タンパク質分解 (TPD) は、難治性標的へのアクセス制限や薬剤耐性の発現など、従来の低分子薬剤の限界を克服することが期待される、強力かつ急成長中の新しい治療手段です。主要な製薬企業ではTPDの導入を進め、重要な技術プラットフォームとして活用を図っています。また、TPD技術に特化した企業では現在、医薬品候補の治験を進めています。一方、多くのバイオテクノロジー企業は、TPD技術を加えることで自社のプラットフォームを多様化させています。

当レポートでは、世界の標的タンパク質分解 (TPD) の市場について業界側の観点から分析し、TPDの専業企業・多角的技術企業のプロファイル (業績、資本取引動向など) や、大手製薬企業がこの業界で果たしている役割、新規のTPD技術の概略、大手製薬企業におけるTPD技術の選択・活用状況、主な上市済み製品および開発中の技術の概略、といった情報を取りまとめてお届けいたします。

目次

略語

第1章 エグゼクティブサマリー

第2章 イントロダクション・概要・調査手法

第3章 TPDのステークホルダーの分析

  • 標的タンパク質分解 (TPD) 技術の企業
    • 概要
    • 分子接着剤・一価プロテアソーム分解物に焦点を当てたTPD専業企業
    • ヘテロ二機能性プロテアソーム分解因子に焦点を当てたTPD専業企業
    • 分子接着剤・ヘテロ二機能性プロテアソーム分解剤に焦点を当てたTPD専業企業
    • リソソーム・オートファジー (非プロテアソーム) 分解技術に焦点を当てたTPD専業企業
    • ヘテロ二機能性プロテアソーム分解物に焦点を当てた多角的技術企業
    • 各種のTPD技術プロファイルを持つ多角的技術企業
    • 各種のTPD技術プロファイルを持つ、その他の技術企業
  • TPDに関心のある製薬企業
    • 主な製薬企業:TPDのステークホルダーとしての概要
    • TPDの研究開発における主要な製薬企業の関心の概略
    • TPDに関する、主要な製薬企業の提携活動の範囲

第4章 TPD技術の分析

  • 分子接着剤・一価プロテアソームTPD技術の分析
  • ヘテロ二機能性プロテアソームTPD技術の分析
  • リソソーム・オートファジー経路TPD技術の分析

第5章 TPDのパイプライン・標的・製品候補の分析

  • 分子接着剤および一価プロテアソーム標的タンパク質分解物
    • 分子接着剤分解剤の臨床および非臨床開発パイプライン:ターゲットと経験
    • 前臨床研究開発パイプラインと分子接着剤および一価タンパク質分解物の標的
  • ヘテロ二機能性プロテアソーム標的タンパク質分解物
    • ヘテロ二機能性分解剤の臨床・非臨床開発パイプライン
    • ヘテロ二機能性分解剤の前臨床研究開発パイプライン
    • ヘテロ二機能性プロテアソーム分解物により対処される、POI (分析対象タンパク質) の標的とE3リガーゼ
    • E3リガーゼとバインダー
  • リソソームおよびオートファジー経路タンパク質分解物
  • その他の標的タンパク質分解物

第6章 ビジネス、資金調達、パートナーシップ

第7章 標的タンパク質分解 (TPD) のステークホルダーのプロファイル

  • 分子接着剤・一価プロテアソーム分解物に焦点を当てたTPD専業企業
    • Coho Therapeutics
    • Degron Therapeutics
    • Dunad Therapeutics
    • f5 Therapeutics
    • Monte Rosa Therapeutics
    • Neomorph
    • Plexium
    • Proxygen
    • Seed Therapeutics
    • Venquis Therapeutics
  • ヘテロ二機能性プロテアソーム分解因子に焦点を当てたTPD専業企業
    • Amphista Therapeutics
    • Arvinas
    • Cullgen
    • Dialectic Therapeutics
    • FIMECS
    • Orum Therapeutics
    • PolyProx Therapeutics
    • Ranok Therapeutics
    • Ubix Therapeutics
  • 分子接着剤・ヘテロ二機能性プロテアソーム分解剤に焦点を当てたTPD専業企業
    • AnHorn Medicines
    • C4 Therapeutics
    • Captor Therapeutics
    • Celeris Therapeutics
    • Kymera Therapeutics
    • Pin Therapeutics
    • ProteoVant Therapeutics
    • Uppthera
  • リソソーム・オートファジー (非プロテアソーム) 分解物に焦点を当てたTPD専業企業
    • Lycia Therapeutics
    • AUTOTAC Bio
    • Calporta Therapeutics (acquired by Merck)
    • Caraway Therapeutics
    • Casma Therapeutics
    • PAQ Therapeutics
  • ヘテロ二機能性プロテアソーム分解物に焦点を当てた多角的技術企業
    • Accutar Biotechnology
    • Aurigene Discovery Technologies
    • BeiGene
    • Foghorn Therapeutics
    • Frontier Medicines
    • Haisco Pharmaceutical Group
    • Hinova Pharmaceuticals
    • Jing Medicine Technology
    • Kintor Pharmaceuticals
    • Nurix Therapeutics
    • Polymed Biopharma
    • Progenra
    • Ribon Therapeutics
    • Ryvu Therapeutics
    • VectorY
    • Voronoi (B2S Bio)
    • XPose Therapeutics
  • 各種のTPD技術プロファイルを持つ多角的技術企業
    • Orionis Therapeutics
    • Kangpu Biopharmaceutical Co.
    • BioTheryX
    • Biohaven
    • Vividion Therapeutics (acquired by Bayer)
    • Phoremost
    • Origami Therapeutics
    • Prazer Therapeutics
    • Prelude Therapeutics
  • 各種のTPDテクノロジープロファイルを持つ、その他の技術企業
    • Ascentage Pharmaceuticals
    • Cullinan Oncology
    • Janpix - Centessa Pharmaceuticals
    • JW Pharmaceuticals
    • NeoImmuneTech
    • Salarius Pharmaceuticals
    • HB Therapeutics
    • Isoprene Pharmaceuticals
    • Ligature Therapeutics
    • Trilo Therapeutics
  • TPDに関与している製薬企業
    • AbbVie
    • Almirall
    • Amgen
    • Bayer
    • Biogen
    • Boehringer Ingelheim
    • Bristol Myers Squibb
    • Calico
    • Debiopharm
    • Eisai
    • Eli Lilly
    • Fosun Pharma
    • Gilead Sciences
    • GlaxoSmithKline
    • Janssen
    • Merck & Co.
    • Merck KGaA
    • Novartis
    • Pfizer
    • Roche
    • Sanofi
    • SK Holdings
    • Vertex Pharmaceuticals
  • TPD業界と提携している教育機関
    • Center for Protein Degradation (CPD):Dana-Farber Cancer Institute
    • Centre for Targeted Protein Degradation (CeTPD):University of Dundee
    • Targeted Protein Degradation and Drug Discovery Laboratory:IRB Barcelona

第8章 標的タンパク質分解 (TPD) 技術のプロファイル

  • 分子接着剤・一価TPD技術のプロファイル
    • Allo-Glueプラットフォーム:Orionis
    • DELPhe技術プラットフォーム:Plexium
    • 一価TPD技術:Dunad
    • NExModsプラットフォーム:f5Therapeutics
    • Optigrade技術プラットフォーム:Captor
    • タンパク質恒常性モジュレーター (PHM) :BioTheryX
    • QuEENプラットフォーム:Monte Rosa
    • TORPEDOプラットフォーム:C4Therapeutics
  • ヘテロ二機能性プロテアソームTPD技術のプロファイル
    • ACCU-Degron技術プラットフォーム:Accutar
    • BIGPROタンパク質分解物発見のためのAIMCADDプラットフォーム:AnHorn
    • アーモンド技術:Aurigene
    • アンフィスタデグラダー技術:Amphista
    • AnDC (Antibody neoDegrader Conjugate) 技術:Orum
    • CDAC技術:BeiGene
    • CHAMP (シャペロンを介したタンパク質分解) 技術:Ranok
    • デグラデューサー技術:Ubix
    • DELigase技術プラットフォーム:Nurix
    • 「ドラッグできないターゲットをドラッグする」創薬プラットフォーム:Frontier
    • Pegasus 創薬プラットフォーム:Kymera
    • PROTAC創薬エンジン:Arvinas
    • RaPPIDS技術プラットフォーム:FIMECS
    • SITESEEKER標的発見プラットフォーム:PhoreMost
    • uSMITE技術:Cullgen
  • リソソーム・オートファジー経路TPD技術のプロファイル
    • ATTEC技術:PAQ
    • ADP (オートファジー分解プラットフォーム):Casma
    • AUTOTAC技術:AUTOTAC
    • リソソーム創薬プラットフォーム:Caraway
    • LYTAC技術プラットフォーム:Lycia
    • MoDE (細胞外タンパク質の分子分解剤) プラットフォーム:Biohaven
  • その他のTPD関連技術
    • E3リガンド発見のための化学プロテオミクスプラットフォーム:Vividion
    • ORICISION技術プラットフォーム:Origami

第9章 TPD製品候補のプロファイル

  • 分子接着剤および一価タンパク質分解物
    • AMG-193
    • BRD4一価分解剤
    • BTX-1188
    • CC-90009;エラギドマイド
    • CC-91633;BMS-986397
    • CC-92480
    • CC-99282
    • CFT7455
    • イベルトマイド (CC-220)
    • JPX-1188
    • KPG-121
    • KPG-818
    • MRT-2359
    • SP-3164
  • ヘテロ二機能性プロテアソームTPD
    • AC-176
    • AC0682
    • APG-265
    • ARD-1671
    • ARV-471
    • ARV-766
    • AU-19820
    • バブデガルタミド;ARV-110
    • BCL6タンパク質分解誘導
    • BGB-16673
    • CC-94676
    • CFT1946
    • CFT8634
    • CFT8919
    • CT-03
    • DT2216
    • FHD-609
    • FIM-01
    • GT-19506
    • GT-20029
    • HP518
    • KT-253
    • KT-333
    • KT-413
    • KT-474;SAR444656
    • NX-2127
    • NX-5948
    • RBN012811
    • RNK05047
    • SD-436
    • UBX-303
  • リソソーム・オートファジー経路タンパク質分解物
    • TMEM175プログラム
    • TRPML1モジュレーター
  • その他のTPD:定義されていないもの
    • HB-007
    • Mnk1/2劣化剤
    • PRT-SCA2

第10章 参考文献

付録:競合他社の分析

目次
Product Code: LMFR0036

This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022.

The report provides essential information about and analysis of:

  • Pure-play TPD technology companies (molecular glues, heterobifunctional degraders, lysosomal and autophagic pathway degraders);
  • Diversified technology companies with a TPD platform;
  • Major pharma companies with a stake in TPD (in-house, partnering, licensing, acquisition);
  • Proteasomal protein degrader technologies (heterobifunctional, molecular glue, monovalent degrader);
  • Rational approaches for monofunctional molecular glue discovery at industry scale;
  • Lysosomal and autophagy pathway degrader technologies (LYTACs, AUTOTACs, ATTECs etc);
  • Clinical and preclinical experience with molecular glues and PROTACs;
  • Profiles of TPD Drug Candidates;
  • TPD Pipeline Analysis;
  • Preferred Targets of TPDs;
  • Preferred E3 ligases and their binders;
  • Technologies for discovery of binders to proteins-of-interest and E3 ligases;
  • Venture capital financing of TPD technology companies;
  • Financing by IPO and follow-on public offerings;
  • Revenues from TPD discovery and licensing deals.

Targeted protein degradation is a strongly and rapidly emerging new therapeutic modality based on the promise to overcome limitations of traditional small molecule drug modalities, such as limited access to difficult-to-drug targets and development of drug resistance. TPD technology is being adopted by most major pharmaceutical companies as it is regarded as a key technology platform. Pure-play TPD technology companies make progress by advancing their drug candidates into clinical studies. Many biotech companies are diversifying their platforms by adding TPD technology.

Investors welcome companies with TPD technologies as evidenced by the continuous flow of money to foster development of TPD technology and TPD drug candidates. Since April of 2020, five pure-play TPD technology companies went public and successfully raised a total of US$ 2.14 bln. The average market capitalization of five NASDAQ listed TPD technology companies was US$ 1.5 bln as of March 4, 2022. Series A-E financing rounds of 23 pure-play TPD technology companies brought in a total of US$ 1,778 mln of venture capital and equity investment. Partnering revenues are another important source of funding. As the TPD pipeline is maturing with favorable clinical outcomes, a recent licensing deal for a clinical phase II estrogen receptor PROTAC justified up-front payment and equity investment of US$ 1 bln.

This report describes and analyzes the industry landscape of targeted protein degradation by proteasomal-, lysosomal- and autophagy-targeted technologies. The report is based on information retrieved from 69 technology companies, 23 pharmaceutical companies and three academic institutions with publicly known industry ties.

The report includes Tables which summarize specific information to allow comprehensive comparisons. Illustrations are used to explain the mechanism of action of the various TPD technologies, pharmacologic effects and molecular structures.

Whenever possible, the profiles of TPD technology companies address the following aspects:

  • General overview (founders, foundation year, technology source, location, number of employees), non-TPD technologies if applicable;
  • Financial situation and funding history;
  • Technology overview;
  • Partnering;
  • Pipeline.

Description of pharmaceutical companies generally is limited to activities with respect to TPD for publicly known in-house activities, for R&D collaboration and licensing and for acquisitions (Merck, Bayer, Amgen and Bristol Myers Squib).

The heterogenous profiles of the 69 technology companies demands assignation to "clusters" of companies with similar characteristics to allow a systematic comparison of 33 pure-play TPD technology companies focused on proteasomal pathway or non-proteasomal pathway technologies; 26 technologically diversified companies with TPD technologies; and the remainder of 10 companies.

Specific profiles are provided for 31 TPD technologies, separately for proteasomal molecular glue/monovalent degrader; proteasomal heterobifunctional degraders, lysosomal & autophagy pathway degraders and the remainder.

Specific profiles are provided for 48 TPD drug candidates, separately for the same four TPD modalities as for TPD technologies.

All information in the three chapters of Company Profiles, Technology Profiles and Drug Candidate Profiles are fully referenced with 117 scientific references, in most cases with hyperlinks with immediate online access to the source of information (abstracts, Poster, Presentations). Non-scientific references, such as press releases, annual reports or company presentations, are disclosed within the text with an embedded hyperlink leading to the source of information. Details about R&D strategy, collaboration and licensing agreements, acquisitions, financing rounds and sources are described in the company profiles.

What will you find in the report?

  • Profiles of pure-play and diversified Targeted Protein Degrader (TPD technology companies;
  • Description of Big Pharma's role in the field (in-house R&D, partnering, acqusition and investing);
  • Comprehensive description and analysis of emerging proteasomal and lysosomal/autophagic TPD technologies;
  • TPD Technology selection and preferences of major pharma;
  • Analysis of TPD technologies;
  • Technologies for discovery of molecular glues, difficult to drug targets and E3 ligase binders;
  • Pharmacologic profiles of Targeted Protein Degraders (TPD);
  • Target selection, pipeline analysis and competition of drug candidates;
  • Description and analysis of financing rounds (capital raised, investors);
  • Economic terms of collaboration and licensing deals;
  • Sources of financing.

Who will benefit from the report?

  • Venture capital, private equity and investment managers;
  • Managers of Big Pharma venture capital firms;
  • Financial analysts;
  • Business development and licensing (BDL) specialists;
  • CEO, COO and managing directors;
  • Corporate strategy analysts and managers;
  • Chief Technology Officer;
  • R&D Portfolio, Technology and Strategy Management;
  • Clinical and preclinical development specialists.

Table of Contents

Abbreviations

1. Executive Summary

2. Introduction, Overview & Methodology

3. Analysis of TPD Stakeholders

  • 3.1. Targeted Protein Degradation (TPD) Technology Companies
    • 3.1.1. Overview
    • 3.1.2. Pure-Play TPD Companies Focused on Molecular Glue & Monovalent Proteasomal Degraders
    • 3.1.3. Pure-Play TPD Companies Focused on Heterobifunctional Proteasomal Degraders
    • 3.1.4. Pure-Play TPD Companies Focused on Molecular Glue & Heterobifunctional Proteasomal Degraders
    • 3.1.5. Pure-Play TPD Companies Focused on Lysosomal & Autophagic (Non-Proteasomal) Degradation Technologies
    • 3.1.6. Diversified Technology Companies with One Focus on Heterobifunctional Proteasomal Degraders
    • 3.1.7. Diversified Technology Companies with Various TPD Technology Profiles
    • 3.1.8. Remainder of Technology Companies with Various TPD Technology Profiles
  • 3.2. Pharmaceutical Companies with TPD Interests
    • 3.2.1. Overview of Major Pharma Companies as Stakeholders in TPD
    • 3.2.2. Profile of Major Pharma's Interest in Targeted Protein Degradation (TPD) R&D
    • 3.2.3. Scope of Major Pharma's Partnering Activities in Targeted Protein Degradation (TPD)

4. Analysis of TPD Technologies

  • 4.1. Analysis of Molecular Glue & Monovalent Proteasomal TPD Technologies
  • 4.2. Analysis of Heterobifunctional Proteasomal TPD Technologies
  • 4.3. Analysis of Lysosomal & Autophagy Pathway TPD Technologies

5. Analysis of TPD Pipeline, Targets and Product Candidates

  • 5.1. Molecular Glue & Monovalent Proteasomal Targeted Protein Degraders
    • 5.1.1. Clinical & Non-Clinical Development Pipeline of Molecular Glue Degraders: Targets and Experience
    • 5.1.2. Preclinical R&D Pipeline & Targets of Molecular Glue & Monovalent Protein Degraders
  • 5.2. Heterobifunctional Proteasomal Targeted Protein Degraders
    • 5.2.1. Clinical & Non-Clinical Development Pipeline of Heterobifunctional Degraders
    • 5.2.2. Preclinical R&D Pipeline of Heterobifunctional Degraders
    • 5.2.3. Protein-of-Interest Targets and E3 Ligases Addressed by Heterobifunctional Proteasomal Degraders
    • 5.2.4. E3 Ligases and Binders
  • 5.3. Lysosomal & Autophagy Pathway Protein Degraders
  • 5.4. Remainder of Targeted Protein Degraders

6. Business, Financing & Partnering

7. Profiles of Stakeholders in Targeted Protein Degradation (TPD)

  • 7.1. Pure-Play TPD Companies Focused on Molecular Glue & Monovalent Proteasomal Degraders
    • 7.1.1. Coho Therapeutics
    • 7.1.2. Degron Therapeutics
    • 7.1.3. Dunad Therapeutics
    • 7.1.4. f5 Therapeutics
    • 7.1.5. Monte Rosa Therapeutics
    • 7.1.6. Neomorph
    • 7.1.7. Plexium
    • 7.1.8. Proxygen
    • 7.1.9. Seed Therapeutics
    • 7.1.10 Venquis Therapeutics
  • 7.2. Pure-Play TPD Companies Focused on Heterobifunctional Proteasomal Degraders
    • 7.2.1. Amphista Therapeutics
    • 7.2.2. Arvinas
    • 7.2.3. Cullgen
    • 7.2.4. Dialectic Therapeutics
    • 7.2.5. FIMECS
    • 7.2.6. Orum Therapeutics
    • 7.2.7. PolyProx Therapeutics
    • 7.2.8. Ranok Therapeutics
    • 7.2.9. Ubix Therapeutics
  • 7.3. Pure-Play TPD Companies Focused on Molecular Glue & Heterobifunctional Proteasomal Degraders
    • 7.3.1. AnHorn Medicines
    • 7.3.2. C4 Therapeutics
    • 7.3.3. Captor Therapeutics
    • 7.3.4. Celeris Therapeutics
    • 7.3.5. Kymera Therapeutics
    • 7.3.6. Pin Therapeutics
    • 7.3.7. ProteoVant Therapeutics
    • 7.3.8. Uppthera
  • 7.4. Pure-Play TPD Companies Focused on Lysosomal & Autophagic (Non-Proteasomal) Degraders
    • 7.4.1. Lycia Therapeutics
    • 7.4.2. AUTOTAC Bio
    • 7.4.3. Calporta Therapeutics (acquired by Merck)
    • 7.4.4. Caraway Therapeutics
    • 7.4.5. Casma Therapeutics
    • 7.4.6. PAQ Therapeutics
  • 7.5. Diversified Technology Companies with One Focus on Heterobifunctional Proteasomal Degraders
    • 7.5.1. Accutar Biotechnology
    • 7.5.2. Aurigene Discovery Technologies
    • 7.5.3. BeiGene
    • 7.5.4. Foghorn Therapeutics
    • 7.5.5. Frontier Medicines
    • 7.5.6. Haisco Pharmaceutical Group
    • 7.5.7. Hinova Pharmaceuticals
    • 7.5.8. Jing Medicine Technology
    • 7.5.9. Kintor Pharmaceuticals
    • 7.5.10. Nurix Therapeutics
    • 7.5.11. Polymed Biopharma
    • 7.5.12. Progenra
    • 7.5.13. Ribon Therapeutics
    • 7.5.14. Ryvu Therapeutics
    • 7.5.15. VectorY
    • 7.5.16. Voronoi (B2S Bio)
    • 7.5.17. XPose Therapeutics
  • 7.6. Diversified Technology Companies with Various TPD Technology Profiles
    • 7.6.1. Orionis Therapeutics
    • 7.6.2. Kangpu Biopharmaceutical Co.
    • 7.6.3. BioTheryX
    • 7.6.4. Biohaven
    • 7.6.5. Vividion Therapeutics (acquired by Bayer)
    • 7.6.6. Phoremost
    • 7.6.7. Origami Therapeutics
    • 7.6.8. Prazer Therapeutics
    • 7.6.9. Prelude Therapeutics
  • 7.7. Remainder of Techology Companies with Various TPD Technology Profiles
    • 7.7.1. Ascentage Pharmaceuticals
    • 7.7.2. Cullinan Oncology
    • 7.7.3. Janpix - Centessa Pharmaceuticals
    • 7.7.4. JW Pharmaceuticals
    • 7.7.5. NeoImmuneTech
    • 7.7.6. Salarius Pharmaceuticals
    • 7.7.7. HB Therapeutics
    • 7.7.8. Isoprene Pharmaceuticals
    • 7.7.9. Ligature Therapeutics
    • 7.7.10 Trilo Therapeutics
  • 7.8. Pharmaceutical Companies with Stakes in Targeted Protein Degradation
    • 7.8.1. AbbVie
    • 7.8.2. Almirall
    • 7.8.3. Amgen
    • 7.8.4. Bayer
    • 7.8.5. Biogen
    • 7.8.6. Boehringer Ingelheim
    • 7.8.7. Bristol Myers Squibb
    • 7.8.8. Calico
    • 7.8.9. Debiopharm
    • 7.8.10. Eisai
    • 7.8.11. Eli Lilly
    • 7.8.12. Fosun Pharma
    • 7.8.13. Gilead Sciences
    • 7.8.14. GlaxoSmithKline
    • 7.8.15. Janssen
    • 7.8.16. Merck & Co.
    • 7.8.17. Merck KGaA
    • 7.8.18. Novartis
    • 7.8.19. Pfizer
    • 7.8.20. Roche
    • 7.8.21. Sanofi
    • 7.8.22. SK Holdings
    • 7.8.23. Vertex Pharmaceuticals
  • 7.9. Academia with TPD Industry Partnerships
    • 7.9.1. Center for Protein Degradation (CPD) at Dana-Farber Cancer Institute
    • 7.9.2. Centre for Targeted Protein Degradation (CeTPD) at University of Dundee
    • 7.9.3. Targeted Protein Degradation and Drug Discovery Laboratory at IRB Barcelona

8. Profiles of Targeted Protein Degradation (TPD) Technologies

  • 8.1. Profiles of Molecular Glue & Monovalent TPD Technologies
    • 8.1.1. Allo-Glue Platform - Orionis
    • 8.1.2. DELPhe Technology Platform - Plexium
    • 8.1.3. Monovalent TPD Technology - Dunad
    • 8.1.4. NExMods Platform - f5 Therapeutics
    • 8.1.5. Optigrade Technology Platform - Captor
    • 8.1.6. Protein Homeostatic Modulators (PHM) - BioTheryX
    • 8.1.7. QuEEN Platform - Monte Rosa
    • 8.1.8. TORPEDO Platform - C4 Therapeutics
  • 8.2. Profiles of Heterobifunctional Proteasomal TPD Technologies
    • 8.2.1. ACCU-Degron Technology Platform - Accutar
    • 8.2.2. AIMCADD Platform for Discovery of BIGPRO Protein Degraders - AnHorn
    • 8.2.3. ALMOND Technology - Aurigene
    • 8.2.4. Amphista Degrader Technology - Amphista
    • 8.2.5. Antibody neoDegrader Conjugate (AnDC) Technology - Orum
    • 8.2.6. CDAC Technology - BeiGene
    • 8.2.7. Chaperone-Mediated Protein Degradation (CHAMP) Technology - Ranok
    • 8.2.8. Degraducer Technology - Ubix
    • 8.2.9. DELigase Technology Platform - Nurix
    • 8.2.10. "Drug the Undruggable Targets" Discovery Platform - Frontier
    • 8.2.11. Pegasus Drug Discovery Platform - Kymera
    • 8.2.12. PROTAC Discovery Engine - Arvinas
    • 8.2.13. RaPPIDS Technology Platform - FIMECS
    • 8.2.14. SITESEEKER Target Discovery Platform - PhoreMost
    • 8.2.15. uSMITE Technology - Cullgen
  • 8.3. Profiles of Lysosomal & Autophagy Pathway TPD Technologies
    • 8.3.1. ATTEC Technology - PAQ
    • 8.3.2. Autophagy Degrader Platform (ADP) - Casma
    • 8.3.3. AUTOTAC Technology - AUTOTAC
    • 8.3.4. Lysosomal Drug Discovery Platform - Caraway
    • 8.3.5. LYTAC Technology Platform - Lycia
    • 8.3.6. Molecular Degrader of Extracellular Protein (MoDE) Platform - Biohaven
  • 8.4. Other TPD-Related Technologies
    • 8.4.1. Chemoproteomics Platform for Discovery of E3 Ligands - Vividion
    • 8.4.2. ORICISION Technology Platform - Origami

9. Profiles of TPD Product Candidates

  • 9.1. Molecular Glue & Monovalent Protein Degraders
    • 9.1.1. AMG-193
    • 9.1.2. BRD4 Monovalent Degrader
    • 9.1.3. BTX-1188
    • 9.1.4. CC-90009; Eragidomide
    • 9.1.5. CC-91633; BMS-986397
    • 9.1.6. CC-92480
    • 9.1.7. CC-99282
    • 9.1.8. CFT7455
    • 9.1.9. Iberdomide (CC-220)
    • 9.1.10. JPX-1188
    • 9.1.11. KPG-121
    • 9.1.12. KPG-818
    • 9.1.13. MRT-2359
    • 9.1.14. SP-3164
  • 9.2. Heterobifunctional Proteasomal Targeted Protein Degraders
    • 9.2.1. AC-176
    • 9.2.2. AC0682
    • 9.2.3. APG-265
    • 9.2.4. ARD-1671
    • 9.2.5. ARV-471
    • 9.2.6. ARV-766
    • 9.2.7. AU-19820
    • 9.2.8. Bavdegalutamide; ARV-110
    • 9.2.9. BCL6 PROTAC
    • 9.2.10. BGB-16673
    • 9.2.11. CC-94676
    • 9.2.12. CFT1946
    • 9.2.13. CFT8634
    • 9.2.14. CFT8919
    • 9.2.15. CT-03
    • 9.2.16. DT2216
    • 9.2.17. FHD-609
    • 9.2.18. FIM-01
    • 9.2.19. GT-19506
    • 9.2.20. GT-20029
    • 9.2.21. HP518
    • 9.2.22. KT-253
    • 9.2.23. KT-333
    • 9.2.24. KT-413
    • 9.2.25. KT-474; SAR444656
    • 9.2.26. NX-2127
    • 9.2.27. NX-5948
    • 9.2.28. RBN012811
    • 9.2.29. RNK05047
    • 9.2.30. SD-436
    • 9.2.31. UBX-303
  • 9.3. Lysosomal & Autophagy Pathway Protein Degraders
    • 9.3.1. TMEM175 Program
    • 9.3.2. TRPML1 Modulators
  • 9.4. Remainder of Targeted Protein Degraders - Not Defined
    • 9.4.1. HB-007
    • 9.4.2. Mnk1/2 Degraders
    • 9.4.3. PRT-SCA2

10. References

ADDENDUM: Competitor Analysis

  • Add 1: Molecular Glue & Monovalent Small Molecule Proteasomal Targeted Protein Degradation
  • Add 2: Heterobifunctional Proteasomal Targeted Protein Degradation
  • Add 3: Lysosomal & Autophagy Pathway Targeted Protein Degradation
  • Add 4: Remainder of Targeted Protein Degradation

Figures & Tables

  • Table 1: Assignation to Clusters of Technology Companies Active in the TPD Field
  • Table 2: Overview of Pure-Play, Cluster 1 Companies - Focused on Molecular Glue & Monovalent Proteasomal Degraders
  • Table 3: Overview of Pure-Play, Cluster 2 Companies - Focused on Heterobifunctional Proteasomal Degraders
  • Table 4: Overview of Pure Play, Cluster 3 Companies - Focused on Molecular Glue & Heterobifunctional Proteasomal Degraders
  • Table 5: Overview of Pure Play, Cluster 4 Companies - Focused on Lysosomal & Autophagy (Non-Proteasomal) Degraders
  • Table 6: Overview of Diversified Cluster 5 Companies - with One Focus on Heterobifunctional Proteasomal Degraders
  • Table 7: Overview of Diversified Cluster 6 Companies with Various TPD Technology Profiles
  • Table 8: Overview of Cluster 7 Companies with Various TPD Technology Profiles
  • Table 9: Overview of Major Pharma Stakes in TPD
  • Table 10: Profile of Major Pharma's Interests in Targeted Protein Degradation (TPD) R&D
  • Table 11: Scope of Major Pharma's Partnering Activities in Targeted Protein Degradation (TPD)
  • Table 12: Overview of Molecular Glue & Monovalent Proteasomal Protein Degrader Discovery Technologies
  • Table 13: Overview of Heterobifunctional Proteasomal Protein Degrader Discovery Technologies
  • Table 14: Overview of Lysosomal & Autophagic Pathway TPD Discovery Technologies
  • Table 15: Overview of Remainder of TPD Discovery Technologies
  • Table 16: Overview of Targeted Protein Degrader (TPD) Pipeline
  • Table 17: Pipeline of Clinical & Non-Clinical Development Stage Molecular Glue & Monovalent Protein Degraders
  • Table 18: Preclinical Pipeline and Targets of Molecular Glue & Monovalent Protein Degraders
  • Table 19: Pipeline of Clinical & Non-Clinical Development Stage Heterobifunctional Proteasomal Protein Degraders
  • Table 20: Preclinical Pipeline of Heterobifunctional Proteasomal Protein Degraders
  • Table 21: Overview of Proteins-of-Interest for Heterobifunctional Proteasomal Degraders
  • Table 22: Lysosomal Pathway Targeted Protein Degraders
  • Table 23: Autophagy Pathway Protein Degraders
  • Table 24: Remainder of Targeted Protein Degraders
  • Table 25: Sources of Financing for TPD Technology Companies
  • Table 26: Investors of TPD Technology Companies
  • Table 27: Partnering Terms of Agreements between TPD Technology Companies and Major Pharmaceutical Companies
  • Table 28: Molecular Glue Degrader Pipeline of Monte Rosa Therapeutics
  • Table 29: Discovery Pipeline of Plexium's DELPhe-Derived Targeted Protein Degraders
  • Table 30: Overview of Arvinas' Partnerships for Targeted Protein Degradation
  • Table 31: Arvinas' PROTAC Degrader Pipeline
  • Table 32: C4 Therapeutics' Proprietary MonoDAC & BiDAC Pipeline
  • Table 33: Targeted Protein Degrader Pipeline of Captor Therapeutics
  • Table 34: Kymera Therapeutics' Pipeline of Targeted Protein Degraders
  • Table 35: Targeted Protein Degrader Pipeline of Proteoant Therapeutics
  • Table 36: AUTOTAC Discovery Programs of AUTOTAC Bio
  • Table 37: Accutar Biotechnology's Pipeline of Small Molecule Chimeric Degraders
  • Table 38: Targeted Protein Degrader Pipeline of Aurigene Discovery Technologies
  • Table 39: Foghorn Therapeutics' Targeted Protein Degrader Pipeline
  • Table 40: Nurix Therapeutics' Pipeline of Protein Degradation Chimeric Targeting Molecules (CTMs)
  • Table 41: Kangpu Biopharmaceuticals' Pipeline of Cereblon Modulators
  • Table 42: Discovery of SPiDEM Molecules for Targeted Protein Degradation by Prazer Therapeutics
  • Table 43: CELMoD R&D Pipeline of Bristol Myers Squibb